Biomarkers for early detection of pancreatic cancer – miRNAs as a potential diagnostic and therapeutic tool?

References

• Gall TMH, Gerrard G, Frampton AE, Castellano L, Ahmad R, Habib N, Spalding D, Pai M, Foroni L, Jiao LR. Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? Oncotarget. 2019 Jan 22;10(7):696–706. doi:10.18632/oncotarget.26511.
   PubMedGoogle Scholar
• Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The use of biomarkers in early diagnostics of pancreatic cancer. Can J Gastroenterol Hepatol 2018 Aug 14;2018:5389820. doi:10.1155/2018/5389820..
   PubMed Web of Science ®Google Scholar
• Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 2020 Jan 28;10(1):1332. doi:10.1038/s41598-020-57930-x.
   PubMed Web of Science ®Google Scholar
• Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2015 Mar;25(3):137–147. doi:10.1016/j.tcb.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016 Jan;231(1):25–30. doi:10.1002/jcp.25056.
   PubMed Web of Science ®Google Scholar
• Hawksworth G, Hales J, Martinez F, Hynes A, Hamilton A, Fernandez V. 2019. Pancreatic cancer trends in Europe: epidemiology and risk factors. Med Stud/Studia Medyczne. 35(2):164–171. doi:10.5114/ms.2019.86336.
   Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941–1953. doi:10.1002/ijc.31937.
   PubMed Web of Science ®Google Scholar
• Lee B, Gibbs P. Inflammation, biomarkers and immuno-oncology pathways in pancreatic cancer. J Pers Med. 2019 Apr 26;9(2):20. doi:10.3390/jpm9020020.
   Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019 Jun 27;4:50. doi:10.21037/tgh.2019.06.02.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson, Hruban RH, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016 Apr 21;2:16022. doi:10.1038/nrdp.2016.22.
   PubMed Web of Science ®Google Scholar
• Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, et al. New therapeutic targets in pancreatic cancer. Cancer Treat Rev. 2019 Dec;81:101926. doi:10.1016/j.ctrv.2019.101926.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr;17(4):500–503. doi:10.1038/nm.2344
   PubMed Web of Science ®Google Scholar
• Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015 Oct;47(10):1168–1178. doi:10.1038/ng.3398
   PubMed Web of Science ®Google Scholar
• Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019 Jun;156(8):2242–2253.e4. doi:10.1053/j.gastro.2019.02.037
   PubMed Web of Science ®Google Scholar
• Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 2017 Jun 1 3(6):774–783. doi:10.1001/jamaoncol.2016.3916.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26 518(7540):495–501. doi:10.1038/nature14169.
   PubMed Web of Science ®Google Scholar
• Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR. Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol. 2017 Jun;44:153–169. doi:10.1016/j.semcancer.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med. 2018 Jun;50(4):277–287. doi:10.1080/07853890.2018.1453168.
   PubMed Web of Science ®Google Scholar
• Elsherif SB, Virarkar M, Javadi S, Ibarra-Rovira JJ, Tamm EP, Bhosale PR. Pancreatitis and PDAC: association and differentiation. Abdom Radiol (NY). 2020 May;45(5):1324–1337. doi:10.1007/s00261-019-02292-w.
   PubMed Web of Science ®Google Scholar
• Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, et al. 2019. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol. 14(1):1–18. doi:10.5114/pg.2019.83422.
   PubMed Web of Science ®Google Scholar
• Klöppel G, Adsay NV. Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. Arch Pathol Lab Med. 2009 Mar;133(3):382–387. doi:10.1043/1543-2165-133.3.382.
   PubMed Web of Science ®Google Scholar
• Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andrén-Sandberg A, Domellöf L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993 May 20;328(20):1433–1437. doi:10.1056/NEJM199305203282001.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al. European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8 304(10):1073–1081. doi:10.1001/jama.2010.1275.
   PubMed Web of Science ®Google Scholar
• Singh RR, O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs. 2020 May;80(7):647–669. doi:10.1007/s40265-020-01304-0.
   PubMed Web of Science ®Google Scholar
• Singh RR, Goldberg J, Varghese AM, Yu KH, Park W. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: a scoping review. Cancer Treat Rev. 2019;27–38. doi:10.1016/j.ctrv.2019.03.003.
   PubMed Web of Science ®Google Scholar
• Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, et al. American Cancer of the Pancreas Screening (CAPS) Consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012 Apr;142(4):796–804;quiz e14-5. doi:10.1053/j.gastro.2012.01.005
   PubMed Web of Science ®Google Scholar
• Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology. 2019 May;156(7):2024–2040. doi:10.1053/j.gastro.2019.01.259.
   PubMed Web of Science ®Google Scholar
• Gong R, Jiang Y. Non-coding RNAs in pancreatic ductal adenocarcinoma. Front Oncol. 2020 Mar 17;10:309. doi:10.3389/fonc.2020.00309.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993 Dec 3;75(5):843–854. doi:10.1016/0092-8674(93)90529-y.
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010 Sep;11(9):597–610. doi:10.1038/nrg2843.
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006 Apr;6(4):259–269. doi:10.1038/nrc1840.
   PubMed Web of Science ®Google Scholar
• An X, Sarmiento C, Tan T, Zhu H. Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 2017 Jan;7(1):38–51. doi:10.1016/j.apsb.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012 Mar;58(3):610–618. doi:10.1373/clinchem.2011.172767
   PubMed Web of Science ®Google Scholar
• Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, et al. Pancreatic juice exosomal MicroRNAs as biomarkers for detection of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019 Jul;26(7):2104–2111. doi:10.1245/s10434-019-07269-z
   PubMed Web of Science ®Google Scholar
• Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014 Jan 22-29 311(4):392–404. doi:10.1001/jama.2013.284664.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang J, Wang F, Yan Z, Liu G, Ma Y, Zhu W, Li Y, Xie L, Bazhin AV, et al. Differential MicroRNA expression profiles as potential biomarkers for pancreatic ductal adenocarcinoma. Biochemistry (Mosc). 2019 May;84(5):575–582. doi:10.1134/S0006297919050122
   PubMed Web of Science ®Google Scholar
• Ma Q, Wu H, Xiao Y, Liang Z, Liu T. Upregulation of exosomal microRNA-21 in pancreatic stellate cells promotes pancreatic cancer cell migration and enhances Ras/ERK pathway activity. Int J Oncol. 2020 Apr;56(4):1025–1033. doi:10.3892/ijo.2020.4986.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu B, Sun S, Lan L, Chen Y, Han S, Li X, Li Z. Downregulation of miR-486-5p enhances the anti-tumor effect of 5-Fluorouracil on pancreatic cancer cells. Onco Targets Ther. 2020 Feb 24;13:1649–1659. doi:10.2147/OTT.S231153.
   PubMed Web of Science ®Google Scholar
• Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N, Shimosegawa T. miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun. 2013 Aug 2;437(3):433–439. doi:10.1016/j.bbrc.2013.06.097.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhao N, Cui J, Wu H, Xiong J, Peng T. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Cell Oncol (Dordr). 2020 Feb;43(1):123–136. doi:10.1007/s13402-019-00476-6.
   PubMed Web of Science ®Google Scholar
• Xu YF, Hannafon BN, Khatri U, Gin A, Ding WQ. The origin of exosomal miR-1246 in human cancer cells. RNA Biol. 2019 Jun;16(6):770–784. doi:10.1080/15476286.2019.1585738.
   PubMed Web of Science ®Google Scholar
• Khan IA, Rashid S, Singh N, Rashid S, Singh V, Gunjan D, Das P, Dash NR, Pandey RM, Chauhan SS, et al. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma. Sci Rep. 2021 Feb 2 11(1):2824. doi:10.1038/s41598-021-82266-5.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang J, Cui W, Liu Y, Zhou H, Wang Y, Chen X, Chen X, Wang Z. Serum exosomal miRNA-1226 as potential biomarker of pancreatic ductal adenocarcinoma. Onco Targets Ther. 2021 Feb 26;14:1441–1451. doi:10.2147/OTT.S296816.
   PubMed Web of Science ®Google Scholar
• Miao H, Lu J, Guo Y, Qiu H, Zhang Y, Yao X, Li X, Lu Y. LncRNA TP73-AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA −200a sponging. J Cell Mol Med. 2021 Mar 8;25(7):3654–3664. doi:10.1111/jcmm.16425.
   PubMed Web of Science ®Google Scholar
• Yao LC, Jiang XH, Yan SS, Wang W, Wu L, Zhai LL, Xiang F, Ji T, Ye L, Tang ZG. Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway. Oncol Lett. 2021 Apr;21(4):326. doi:10.3892/ol.2021.12588.
   PubMed Web of Science ®Google Scholar
• Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014 Mar;18(3):371–390. doi:10.1111/jcmm.12236.
   PubMed Web of Science ®Google Scholar
• Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakravarti A. Circulating microRNAs in cancer: hope or hype? Cancer Lett. 2016 Oct 10;381(1):113–121. doi:10.1016/j.canlet.2016.07.002.
   PubMed Web of Science ®Google Scholar
• Keller A, Meese E. Can circulating miRNAs live up to the promise of being minimal invasive biomarkers in clinical settings? Wiley Interdiscip Rev RNA. 2016 Mar-Apr;7(2):148–156. doi:10.1002/wrna.1320.
   PubMed Web of Science ®Google Scholar
• Masè M, Grasso M, Avogaro L, D’Amato E, Tessarolo F, Graffigna A, Denti MA, Ravelli F. Selection of reference genes is critical for miRNA expression analysis in human cardiac tissue. A focus on atrial fibrillation. Sci Rep. 2017 Jan 24;7:41127. doi:10.1038/srep41127.
   PubMed Web of Science ®Google Scholar
• Witwer KW. Circulating microRNA biomarker studies: pitfalls and potential solutions. Clin Chem. 2015 Jan;61(1):56–63. doi:10.1373/clinchem.2014.221341.
   PubMed Web of Science ®Google Scholar
• Fasching PA, Brucker SY, Fehm TN, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Häberle L, Taran FA, et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network. Geburtshilfe Frauenheilkd. 2015 Jan;75(1):41–50. doi:10.1055/s-0034-1396215
   PubMed Web of Science ®Google Scholar
• Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018 Oct 1;36(28):2887–2894. doi:10.1200/JCO.2017.77.6658.
   PubMed Web of Science ®Google Scholar